Evidence map›Paper›PMID 30662810›Full record

ArticleAmerican journal of cancer research2018

Local and systemic Curcumin C3 complex inhibits 4NQO-induced oral tumorigenesis

Alok R Khandelwal, Tara Moore-Medlin, Oleksandr Ekshyyan, Xin Gu, Fleurette Abreo, Cherie-Ann O Nathan

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Implementing Curcumin in Translational Oncology Research.Molecules (Basel, Switzerland) · 2020
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alok R KhandelwalDepartment of Otolaryngology-Head & Neck Surgery, LSU Health-Shreveport Shreveport 71130-3932, LA, USA.
Tara Moore-MedlinDepartment of Otolaryngology-Head & Neck Surgery, LSU Health-Shreveport Shreveport 71130-3932, LA, USA.
Oleksandr EkshyyanDepartment of Otolaryngology-Head & Neck Surgery, LSU Health-Shreveport Shreveport 71130-3932, LA, USA.
Xin GuDepartment of Pathology, LSU-Health Shreveport Shreveport 71130-3932, LA, USA.
Fleurette AbreoDepartment of Pathology, LSU-Health Shreveport Shreveport 71130-3932, LA, USA.
Cherie-Ann O NathanDepartment of Otolaryngology-Head & Neck Surgery, LSU Health-Shreveport Shreveport 71130-3932, LA, USA.
Louisiana State University Health Sciences Center Shreveport · USOverton Brooks VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and Neck Squamous cell carcinoma (HNSCC) can be characterized by synchronous tumors in the upper aerodigestive tract. Second primary tumors as a result of field cancerization are a significant problem amongst patients with risk factors for HNSCC, indicating a need for chemo preventive agents. We investigated the efficacy of local and systemic Curcumin C3 complex (C3); a purified mixture of Curcumin, bisdemethoxy Curcumin and demethoxy Curcumin as a chemo preventative agent in 4-nitroquinoline-1-oxide (4NQO)-induced tumorigenesis in mice. The effect of local C3 application was compared to C3 administered orally and in combination with systemic administration. C57Bl/6 mice were administered 4NQO (50 µg/ml) in the drinking water for 16 weeks. At 12 weeks, mice were subjected to daily treatment with either vehicle (control), or 15 mg C3 complex by local delivery, gavage, or combined local and gavage for 28 days (16 week time point), and followed up to 22 weeks. Compared to local and oral systemic C3 administration, combination of local and systemic application significantly decreased multiplicity of 4NQO-induced preneoplastic and neoplastic lesions (p<0.05). Treatment with C3 correlated with a decrease in cell proliferation compared to the 4NQO group. Further, pre-treatment with C3 complex significantly attenuated 4NQO induced expression of basic fibroblast growth factor (FGF-2) and its cognate receptor FGFR-2, suggesting an important role of FGF-2/FGFR-2 axis in chemoprevention of HNSCC (p<0.05). Our findings suggest that a combination of local and systemic C3 complex could effectively target proliferation and inhibit 4NQO-induced tumorigenesis

Indexed as

4NQOCurcumin C3 complexFGFR-2Oral squamous cell cancer

Identifiers

PMID30662810
PMCPMC6325482
OpenAlexW2996402081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.